A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
Eisai Co., Ltd.
The purpose of this trial is to investigate the safety and tolerability of perampanel in
long- term treatment in the patients with refractory partial epilepsy (uncontrolled with
other anti-epileptic drugs) who completed Week 10 of Phase II Study E2007-J081-231 study.
To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures
This will be a multi-center, randomized, double-blind, placebo-controlled, crossover study to
evaluate the effects of 2007/Fycompa (perampanel) on sleep, in subjects with well controlled
partial onset seizures (on an antiepileptic drug [AED] monotherapy) who are experiencing
sleep onset insomnia.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.